Recent Updates
Recently added Catalysts
ALT Positive Sentiment

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Wednesday, November 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Altimmune, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 2:30 p.m. ET. The session will feature members of the management team in a fireside chat format. The event will be accessible via webcast on the Altimmune website, highlighting the company's focus on novel peptide-based therapeutics.
Price reaction · baseline $5.14 (2025-11-25 close) · hit pre-market · 1 other ALT headline(s) in the window, move may be shared
day 0 close · peak
+0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Altimmune is participating in a significant healthcare conference.
  • The company is developing innovative therapeutics for liver and cardiometabolic diseases.
  • The webcast allows broader access to the company's updates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight

Full Press Release Details

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) --Altimmune, Inc.(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37thAnnual Healthcare Conference. Details are as follows:

Conference:Piper Sandler 37thAnnual Healthcare ConferenceDate/Time:Wednesday, December 3, 2025 at 2:30 p.m. ET

The session will be webcast and can be accessed by visiting theEventssection of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visitwww.altimmune.com.

Follow @Altimmune, Inc. onLinkedInFollow @AltimmuneInc onX

Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com

Media Contact:Savannah ValadeReal Chemistryaltimmune@realchemistry.com

This press release was published by a CLEAR® Verified individual.

Frequently Asked Questions

When will Altimmune participate in the conference?

Altimmune will participate in the conference on December 3, 2025, at 2:30 p.m. ET.

What is the format of Altimmune's presentation?

The presentation will be in a fireside chat format featuring the management team.

How can I access the conference webcast?

The webcast can be accessed via the Events section of the Altimmune website.

What is Altimmune's lead product candidate?

Altimmune's lead product candidate is pemvidutide, targeting metabolic dysfunction-associated diseases.

ShareAdd on Google
Tags: ALT Viatris Investor Conferences Healthcare Altimmune Piper Sandler healthcare conference pemvidutide biopharmaceuticals
Last updated: Nov 26, 2025

Biotech snapshot

Cash runway
$519M liquidity · $8M/mo burn
~64 mo
Minimal dilution risk
Lead asset
ALT-801Phase 2
Obesity/Overweight →

Catalyst track record

+22%
best trade around ALT's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ALT.

See every catalyst's timing & PoA →